develop
novel
tuberculosi
tb
vaccin
combin
dna
vaccin
express
mycobacteri
heat
shock
protein
interleukin
deliv
hemagglutin
viru
japan
hvj
envelop
liposom
express
vector
encod
singlechain
protein
compris
subunit
construct
vaccin
provid
remark
protect
efficaci
mous
guinea
pig
model
compar
bcg
vaccin
basi
cfu
number
tb
surviv
induct
posit
ctl
activ
improv
histopatholog
tuberculosi
lesion
vaccin
also
provid
therapeut
efficaci
multidrug
resist
tb
mdrtb
extrem
drug
resist
tb
xdrtb
prolong
surviv
time
decreas
number
tb
lung
murin
model
furthermor
extend
studi
cynomolgu
monkey
model
current
best
anim
model
human
tuberculosi
novel
vaccin
provid
higher
level
protect
efficaci
bcg
base
upon
assess
mortal
esr
bodi
weight
chest
xray
find
immun
respons
monkey
control
group
salin
die
within
month
monkey
group
surviv
month
postinfect
termin
period
experi
furthermor
bcg
prime
vaccin
booster
primingboost
method
show
synergist
effect
tbinfect
cynomolgu
monkey
surviv
contrast
monkey
bcg
tokyo
alon
group
aliv
surviv
furthermor
vaccin
exert
therapeut
efficaci
surviv
augment
immun
respons
tbinfect
monkey
data
indic
novel
dna
vaccin
might
use
mycobacterium
tuberculosi
includ
xdrtb
mdrtb
human
therapeut
clinic
trial
tuberculosi
major
global
threat
human
health
million
peopl
die
everi
year
mycobacterium
tuberculosi
tb
infect
tuberculosi
vaccin
current
avail
attenu
strain
mycobacterium
bovi
bcg
bcg
although
efficaci
adult
tb
diseas
remain
controversi
furthermor
multidrug
resist
tuberculosi
mdrtb
extrem
drug
resist
tb
xdrtb
becom
big
problem
world
circumst
develop
therapeut
vaccin
tb
well
prophylact
vaccin
tb
requir
therefor
recent
develop
novel
tb
vaccin
dna
vaccin
express
mycobacteri
heat
shock
protein
deliv
hemagglutin
viru
japan
hvj
liposom
vaccin
fold
effici
bcg
murin
model
basi
elimin
tuberculosi
mediat
induct
ctl
futhermor
vaccin
use
hvjenvelop
fold
effici
bcg
murin
tbprophylact
model
nonhuman
primat
model
tb
provid
inform
vaccin
develop
fact
previou
studi
evalu
protect
efficaci
cynomolgu
monkey
model
excel
model
human
tuberculosi
present
studi
observ
synergist
effect
bcg
use
primingboost
method
tbinfect
cynomolgu
monkey
combin
two
vaccin
show
strong
prophylact
efficaci
tuberculosi
surviv
seen
previous
murin
model
tb
moreov
evalu
therapeut
effect
vaccin
mdrtb
infect
xdrtb
infect
murin
monkey
model
indic
vaccin
exert
therapeut
efficaci
tb
mdrtb
xdrtb
dna
vaccin
encod
mtuberculosi
human
encapsul
hvjenvelop
hvjliposom
ctl
activ
assess
c
r
releas
assay
week
intraven
challeng
mtuberculosi
number
cfu
lung
spleen
liver
count
therapeut
efficaci
hvjenvelop
dna
vaccin
evalu
therapeut
efficaci
also
evalu
chronic
tb
infect
model
mice
use
aerosol
challeng
tb
madison
aerosol
exposur
chamber
univers
wisconsin
cynomolgu
monkey
hous
bl
anim
facil
leonard
wood
memori
research
center
anim
vaccin
nine
time
hvjenvelop
express
plasmid
human
im
one
week
challeng
mtuberculosi
erdman
strain
intratrach
instil
immun
respons
surviv
examin
describ
previou
studi
control
group
salin
die
within
month
monkey
group
surviv
month
postinfect
termin
period
experi
data
shown
protect
efficaci
surviv
bcg
use
primingboost
method
tb
challeng
cynomolgu
monkey
day
tb
use
cynomolgu
monkey
model
furthermor
use
monkey
protect
efficaci
hvj
bcg
use
primingboost
method
tb
infect
cynomolgu
monkey
strong
four
monkey
group
bcgprime
dna
vaccin
dna
vaccin
booster
aliv
month
postinfect
contrast
monkey
bcg
tokyo
group
aliv
surviv
monkey
salin
control
group
dna
vaccineprim
bcg
tokyo
vaccin
booster
group
respect
aliv
month
studi
addit
improv
esr
chest
xray
find
product
augment
group
vaccin
bcg
vaccineprim
dna
vaccineboost
furthermor
prolifer
pbl
strongli
enhanc
taken
togeth
result
clearli
demonstr
bcg
prime
booster
could
provid
extrem
strong
protect
efficaci
mtuberculosi
cynomolgu
monkey
model
surviv
vaccin
mice
xdrtb
extrem
drug
resist
tb
investig
mice
control
group
die
tb
within
day
xdrtb
infect
contrast
mice
treat
dna
prolong
surviv
period
significantli
statist
analysi
p
data
shown
demonstr
vaccin
therapeut
activ
xdrtb
tabl
week
intraven
challeng
mdrtb
cfu
tb
lung
spleen
liver
count
therapeut
efficaci
hvjenvelop
dna
vaccin
evalu
dna
dna
vaccin
treatment
significantli
reduc
bacteri
load
mdrtb
compar
salin
control
group
p
therapeut
efficaci
dna
dna
also
observ
use
vivo
human
immun
model
receptor
chain
disrupt
nodscid
mice
construct
human
pbl
scidpblhu
therapeut
vaccin
dna
group
result
significantli
therapeut
activ
even
scidpblhu
mice
exert
human
cell
immun
respons
tabl
immun
respons
cynomolgu
monkey
week
challeng
mtuberculosi
erdman
strain
intratrach
instil
augment
prolifer
pbl
therapeut
vaccin
monkey
group
dna
dna
augment
data
shown
vaccin
also
improv
surviv
monkey
compar
salin
control
group
tb
challeng
five
monkey
group
vaccin
aliv
surviv
contrast
monkey
salin
control
group
aliv
surviv
result
demonstr
vaccin
could
provid
strong
therapeut
efficaci
tb
mdrtb
xdrtb
cynomolgu
monkey
model
well
murin
model
vaccin
exert
signific
prophylact
effect
tb
indic
extens
surviv
year
improv
esr
chest
xray
find
increas
bodi
weight
augment
immun
respons
cynomolgu
monkey
model
close
mimic
human
tb
diseas
import
evalu
long
surviv
period
monkey
model
human
tb
chronic
infect
diseas
furthermor
decreas
bodi
weight
tb
patient
usual
accompani
progress
diseas
dna
vaccin
rel
new
approach
immun
infecti
diseas
prophylact
therapeut
dna
vaccin
establish
use
sever
kind
vector
hvjliposom
hvjenvelop
adenoviru
vector
adenoassoci
viru
vector
aav
lentiviru
vector
develop
hemagglutin
viru
japan
envelop
hvjenvelop
use
inactiv
sendai
viru
nonvir
vector
drug
deliveri
deliv
effici
dna
sirna
protein
anticanc
drug
cell
vitro
vivo
therefor
hvjenvelop
use
effici
safe
vector
dna
vaccin
tb
present
studi
va
ccin
e
ou
se
gu
ea
pig
mon
k
ey
scidp
blh
u
h
u
n
hvj
e
n
velop
dna
dna
dna
dna
pla
n
pla
n
th
er
ap
eu
tic
effect
pla
n
u
lysin
recombin
n
gr
n
u
lysin
th
er
peu
tic
e
ffect
pla
n
gra
n
u
lysin
dna
th
er
peu
tic
e
ffect
pla
n
guinea
pig
model
provid
better
protect
pulmonari
patholog
caus
pulmonari
infect
tb
bcg
vaccin
data
shown
present
studi
demonstr
bcg
vaccin
prime
booster
could
provid
extrem
strong
surviv
efficaci
mtuberculosi
compar
bcg
alon
surviv
cynomologu
monkey
model
japan
countri
bcg
vaccin
inocul
human
infant
birth
therefor
bcg
prime
infant
booster
adult
includ
junior
high
school
student
high
school
student
old
person
may
requir
signific
improv
clinic
protect
efficaci
tb
furthermor
vaccin
exert
signific
therapeut
effect
tb
indic
extens
surviv
mice
infect
xdrtb
decreas
cfu
tb
lung
liver
spleen
mice
infect
mdrtb
well
drugsensit
tb
decreas
cfu
tb
organ
mice
challeng
tb
vivo
human
immun
model
scidpblhu
augment
immun
respons
cynomologu
monkey
model
close
mimic
human
tb
diseas
import
evalu
surviv
monkey
increas
surviv
rate
monkey
treat
vaccin
observ
compar
control
monkey
treat
salin
increas
surviv
rate
monkey
treat
dna
also
strongli
observ
therapeut
model
monkey
tabl
recent
studi
demonstr
granulysin
vaccin
show
therapeut
efficaci
tb
mice
tabl
therefor
combin
therapeut
vaccin
might
use
futur
mdrtb
xdrtb
becom
big
problem
world
new
patient
mdrtb
shown
everi
year
howev
effect
drug
mdrtb
vaccin
exert
therapeut
activ
even
xdrtb
resist
rfp
inh
sm
eb
km
evm
th
pa
lvfx
pza
sensit
cs
thu
result
dna
vaccin
murin
therapeut
model
cynomolgu
monkey
therapeut
model
provid
signific
rational
move
vaccin
clinic
trial
furthermor
establish
chronic
tb
diseas
model
use
mous
infect
tb
aerosol
chamber
data
shown
use
model
therapeut
efficaci
vaccin
also
observ
thu
take
advantag
avail
multipl
anim
model
accumul
essenti
data
hvjenvelop
dna
vaccin
anticip
phase
clinic
trial
studi
support
health
labour
scienc
research
grant
mhlw
intern
collabor
studi
grant
human
scienc
foundat
grantinaid
scientif
research
b
ministri
educ
cultur
sport
scienc
technolog
japan
grant
osaka
tuberculosi
foundat
